Received Nov 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU3 | INFLUENZA (SEASONAL) (FLUARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENQUADFI) | SANOFI PASTEUR | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Approximately 8?12 hours after vaccination on 19-Nov-2025, patient developed fever (101.8 °F), chills, sore throat, ear pain, and a rapidly progressive, intensely pruritic maculopapular rash starting on face/trunk and spreading to near-confluent on torso, extremities, palms, and soles (no wheals, no angioedema, no respiratory distress). Treated with oral antihistamines, calamine lotion, and emollients. By day 6?7 post-vaccination: fever and systemic symptoms resolved, itching stopped, all lesions crusted/scabbed over. Current status (25-Nov-2025): recovering/resolving, scabs beginning to fall off, expected full resolution within 1?2 weeks with possible temporary post-inflammatory pigmentation. No hospitalization, no sequelae to date.